

AREA PRESCRIBING COMMITTEE – ACTION LIST 16th JUNE 2016

| Action Reference | Minute Reference | ACTION | OWNER | FURTHER COMMENTS | TARGET DATE | STATUS (R/A/Clear) |
|-------------------------|------------------|---|----------------|--|-------------|--------------------|
| 14/050 | 134/14 | Add second line use of anti-TNFs for psoriatic arthritis in line with the decisions of the IFR panel. | LA | To be added to Blueteq by August 2016 meeting | 11.08.2016 | ONGOING |
| ACTIONS FOR 2016 | | | | | | |
| 15/42 | 26/15 | Annual Declaration of Interest Form To be developed and completed annually by committee members. | LA | Comments back on proposed declarations for the August APC meeting | 11.08.2016 | ONGOING |
| 15/34 | 72/15 | Vitamin D guidelines (was NG 14 Melanoma assessment and Management) Vitamin D guidelines circulated to the group | LA BG PB | Comments to be sent to Ruth O’Neil by end of June. Final draft to be produced by July 11 th for presentation at the provider Medicine Management Group meetings. Final version to be brought to the August APC meeting. | 11.08.2016 | ONGOING |
| 15/39 | 111/15 | Sulfasalazine SCG Review for gastro indications. | PB | Updated version now includes Rheumatology and Gastro indications, PB to update document removing “and ensure that test results are recorded in the monitoring booklet” . | 11.08.2016 | ONGOING |
| 15/43 | 126/15 | Azathioprine & Mercaptopurine SCG To be reviewed in light of gastroenterologist comments. | LA | LA to review the SCG taking comments from Mr Dennis Burke and Dr Shadad (both NCUHT) into account | 11.08.2016 | ONGOING |
| 03/16 | 03/16 | Cumbria and Lancashire Formulary (was Lothian Joint Formulary review) Working group to be set up to discuss the options for formulary in light of discrepancies between Lothian and NICE. | LA | Groups for the formulary review have now been created with section reviews to be completed by mid-September 2016. Lancashire North have joined the project. Final version to be brought to October APC meeting. | 13.10.2016 | ONGOING |
| 04/16 | 08/16 | Transfer of care audit | AL | Audit results have just been received, to be brought to the August APC meeting. | 11.08.2016 | ONGOING |

| | | | | | | |
|-------|---------------|---|----|--|------------|---------|
| 14/16 | 32/16 | Acetyl cholinesterase inhibitors – SCG review | HH | Amendments requested to secondary care responsibilities: include the statement- Discharge letter should state “Prescribe drug in line with SCP” APPROVED with this amendment. Final version to August meeting. | 11.08.2016 | ONGOING |
| 09/16 | 18/16 & 33/16 | Memantine and AChEI – review of RAG rating | HH | Document to be updated by CPFT taking further comments into consideration, including the need for a schedule for introduction of memantine and stop AChEI and monitoring of response. Final draft to be circulated for comments. Final version to next meeting | 11.08.2016 | ONGOING |
| 18/16 | 45/16 | Recent LJF Formulary decisions Botulinum toxin type A 50 unit, 100 unit and 200 unit powder for solution for injection Focal spasticity | AL | AL to check to check that this is not a procedure of limited clinical value | 11.08.2016 | |
| 19/16 | 46/16 | Recent LJF Formulary decisions Botulinum toxin type A 50 and 100 LD50 units powder for solution for injection Post stroke spasticity of the upper limb | AL | AL to check to check that this is not a procedure of limited clinical value | 11.08.2016 | |
| 20/16 | 45/16 | LJF Amendments April 2016 – Chapter 4 CNS | HH | To bring to August APC meeting | 11.08.2016 | |
| 21/16 | 46/16 | NICE Technology Appraisals TA388 Sacubitril valsartan Treating symptomatic chronic heart failure with reduced ejection | BG | Full guidance to be brought to August APC meeting. BG to ask NCUHT clinicians if they wish to develop a SCP. | 11.08.2016 | |

| | | | | | | |
|-------|-------|--|----|---|------------|--|
| | | fraction. | | | | |
| 22/16 | 47/16 | NG46 Controlled Drugs: safe use and management | AL | Cumbria do not have a local opioid conversion table. AL to review existing tables. | 11.08.2016 | |
| 24/16 | 55/16 | Domperidone SCG | PB | To be taken back to the paediatricians at UHBMT for further evidence to support use that is not in line with MHRA guidance. | 11.08.2016 | |
| 25/16 | 56/16 | PICO dressings RAG review | LA | Proposed SCP discussed and changes suggested including name changed to "prescription request form". To be circulated to the DN team for comment, version to the August APC meeting. | 11.08.2016 | |
| 26/16 | 63/16 | Stopping over medication for people with learning difficulties | AL | Further information from the NHSE Call to Action (expected June16) to be brought back to August APC meeting. | 11.08.2016 | |
| 27/16 | 64/16 | Psoriasis Biologics Agents consultation | AL | To be brought to the August APC meeting. | 11.08.2016 | |
| 28/16 | 65/16 | Sequential use of Biologics in Ulcerative Colitis | AL | To be brought to the August APC meeting. | 11.08.2016 | |
| 29/16 | 66/16 | Sequential use of Biologics in Crohn's disease | AL | To be brought to the August APC meeting. | 11.08.2016 | |
| 30/16 | 67/16 | Zero risk schemes in advance of NICE | PB | To be brought to the August APC meeting. | 11.08.2016 | |
| 31/16 | 68/16 | Off-label uses of tablets and capsules The current "Specials Guide – Quick wins" contains many out of date recommendations as licensed alternatives are now available. | LA | Updated version to be brought to October meeting. | 13.10.2016 | |
| 32/16 | 69/16 | Colecalciferol recommendations | BM | BM to send a list to Ruth O'Neil for inclusion | 11.08.2016 | |

| | | | | | | |
|--------------|--------------|---|----|--|------------|--|
| | | Highlighted the recent increase in the number of licensed vitamin D products available. | | in the Vitamin D guidelines. | | |
| 33/6 | 70/17 | Fulvestrant RAG rating The committee approved BLACK rating in view of the time since publication of NICE TA239. | LA | Current prescribing GPs to be informed and SCG to be removed from NECS MO website. | 11.08.2016 | |
| 34/16 | 71/16 | Blueteq The lack of updated forms on Blueteq was highlighted as a risk to clinical engagement with the project. | LA | LA to liaise with Lancashire to ensure updated forms are added to Cumbria system, Benepali® as priority. | 11.08.2016 | |
| 35/16 | 73/16 | Drug Safety Update Drug Safety Update (April 2016) | LA | Points 1, 7, 8 & 9 add to Prescription Pad | 11.08.2016 | |
| 36/16 | 76/16 | Submissions to the APC | PU | Briefing paper to be developed | 11.08.2016 | |

| | |
|--|---------------------------------|
| | New action from current meeting |
| | Action over one meeting old |
| | Action over two meetings old |